Clinical Trial

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-09-09; most recent amendment 2025-12-10.
Status change: Not Yet Recruiting → Recruiting 2025-12-10
Status change: Withdrawn → Not Yet Recruiting 2025-12-08
Status change: Not Yet Recruiting → Withdrawn 2025-11-20
Trial Details
NCT Number NCT07167160
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Conditions Cervical Cancer, Immunochemotherapy
Enrollment 59 participants
Start Date 2025-03-10
Primary Completion 2026-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-18